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Abstract
Regulatory T cells have an important role in limiting immune reactions and are essential regulators
of self-tolerance. Among them, CD4+CD25high regulatory T cells are the best-described subset. In
this article, we summarize current knowledge on the phenotype, function, and development of
CD4+CD25high regulatory T cells. We also review the literature on the role of these T cells in
rheumatic diseases and discuss the potential for their use in immunotherapy.
Introduction
Tolerance to "self" is a major immune regulatory mecha-
nism that protects the body's own tissues from immune-
mediated damages and restricts active immune responses
to those against microbial invaders (Figure 1). A classical
type of tolerance, called central tolerance, is the mecha-
nism by which "forbidden clones" of lymphocytes that
recognize self antigens are eliminated in the thymus dur-
ing normal lymphocyte development [1-3]. However,
some lymphocyte clones with specificities for self antigens
are found in animals and humans without autoimmunity
[4-8]. In addition, autoimmunity can develop in the
absence of defects in central tolerance. These findings ini-
tially led to the hypothesis that peripheral tolerancemust
prevent auto-aggression by self-reactive T cells that escape
thymic deletion. In the 1970s and 1980s, work on periph-
eral tolerance focused on characterization of specific sup-
pressor T cells, the presumed regulators of immune
responses in the periphery [9]. However, attempts to
define and isolate suppressor T cells led to conflicting
results, disappointment, and near abandonment of the
field. With the development of new technologies in the
1990s, compelling evidence was put forward to support
the existence of cellular subsets that possess immunosup-
pressive activities, this time under the name regulatory T
cells[10].
Types of regulatory T cells
There are various types of regulatory T cells, including
TCRαβ+CD4+, TCRαβ+CD8+, TCRαβ+CD4-CD8-, and
TCRγι+ T cells. The majority of recent research has focused
on TCRαβ+CD4+ regulatory T cells, of which there are
several subtypes with distinct surface phenotypes,
cytokine production profiles and mechanisms of immune
suppression. Among the subtypes, T cells produced in the
thymus and delivered to the periphery as a long-lived lin-
eage of self-antigen-specific lymphocytes are called natu-
ral CD4+CD25high regulatory T cells (nTreg). In contrast+,
CD4+ T cells that are recruited from circulating lym-
phocytes and acquire regulatory properties under particu-
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lar conditions of stimulation are called adaptive
Tcells(Figure 2). Two types of adaptive CD4+ regulatory T
cells are type 1 regulatory T cells (Tr1) and T helper 3 reg-
ulatory cells (Th3). Suppressive effects of Tr1 and Th3 cells
are dependent on the production of inhibitory cytokines,
IL-10 and TGF-β, respectively [11-18]. A third type of
adaptive regulatory T cell is the CD4+CD25high T cell
induced in the periphery; these are termed induced regu-
latory T cells (iTreg). iTreg have similar properties to thy-
mus-generated nTreg. Both cell types are anergic and do
not proliferate upon TCR stimulation. Both cell types can
inhibit proliferation of CD4+CD25- T cells in a dose
dependent manner. Despite their characteristic anergy,
CD4+CD25high regulatory T cells cultured with anti-CD3
antibodies (for TCR stimulation) and excess IL-2 (a T cell
growth factor), can proliferate and still retain their sup-
pressive activities. CD4+CD25high regulatory T cells (nTreg
and iTreg) are the subject of this review.
Development of CD4+CD25high regulatory T cells
NTreg arise during normal lymphocyte ontogeny in the
thymus [18,19], and this is thought to be the exclusive site
of nTreg development in children [20]. NTreg represent
5–10% of CD4+CD8- thymocytes in humans, mice, and
rats. It seems likely that nTreg are positively selected
through high-affinity recognition of self peptides pre-
sented by thymic stromal cells. This event, possibly
together with signals from thymic dendritic cells, stimu-
lates production of anti-apoptotic molecules to protect
against negative selection. Recent data also indicate that
CD4+CD25high regulatory T cells have a reciprocal devel-
opmental relationship in with Th17 cells, inflammatory T
helper cells that produce IL-17 [21].
Many aspects of nTreg development in the thymus, such
as their site of development, their interaction with thymic
epithelial cells, and their selection are still poorly under-
stood [22,23]. Despite these uncertainties, it is clear that
the transcription factor forkhead box P3 (Foxp3) plays a
major role in the ontogeny and function of nTreg [23-29].
FoxP3 is preferentially and stably expressed in peripheral
nTreg, even after proliferation [23,27]. However, the sig-
nals that induce the stable up-regulation of Foxp3 and
committed regulatory function in nTreg are not known.
Furthermore, recent research shows that much of the
nTreg transcriptional signature is not ascribable to Foxp3.
It seems that a complex regulatory mechanism upstream
of Foxp3 determines nTreg lineage and is distinct from
elements downstream of Foxp3 that are essential for the
cell's regulatory properties [30]. After their thymic selec-
tion, nTreg populate peripheral tissues. They are believed
to be long-lived and may repeatedly proliferate in the
periphery upon encountering specific self antigens [31-
33]. However, their potential for continuous cell division
is limited, which is thought to be associated with their
diminished telomerase activity compared to CD4+CD25-
T cells [34,35].
The total number of CD4+CD25high regulatory T cells in
human peripheral blood increases with age, despite
thymic involution [36]. The likely explanation is the thy-
mus-independent generation of CD4+CD25high  iTreg.
Mechanisms of immune tolerance Figure 1
Mechanisms of immune tolerance.
Different subsets of regulatory T cells Figure 2
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Several lines of evidences have suggested that induction of
iTreg requires FoxP3. When a Foxp3 gene is transduced
into CD4+CD25- T cells, these cells acquire CD25 surface
expression and other phenotypic characteristics of nTreg.
These transduced CD4+CD25high iTreg are able to inhibit
proliferation and cytokine production in the effector T
cells and the development of some experimental autoim-
mune diseases in animals [37]. Murine and human stud-
ies show that several cytokines are also required for
generation of extra-thymic CD4+CD25high iTreg. Essential
stimuli include TGF-β [17,38-41], IFN-γ [42], anti-CD3/
CD28 antibodies or antigen specific stimulation [43,44],
IL-4/IL-13 [45,46], and thrombospondin-CD47 interac-
tion [46]. Murine studies also show that tolerogenic con-
ditions and homeostatic proliferation during
lymphopenia induce the development of CD4+CD25high
Foxp3+ iTreg in vivo [47-51].
Phenotype of CD4+CD25high regulatory T cells
No specific marker for CD4+CD25high regulatory T cells is
yet known (Figure 3). Foxp3 has been considered the
most reliable marker [23], but is intracellular and cannot
be used for isolation or in vivo tracking of CD4+CD25high
regulatory T cells. In addition, activation of CD4+CD25- T
cells can transiently up-regulate FoxP3 expression in
human cells, although this is not the case in mice
[41,52,53]. Hence, FoxP3 alone may not be a specific
marker for human CD4+CD25high regulatory T cells [53].
Another molecule associated with CD4+CD25high regula-
tory T cells is CD25, the α chain of the IL-2 receptor, Both
nTreg and iTreg constitutively express CD25 and suppres-
sive activity is optimal in CD4+ T cells expressing the
highest levels of CD25 (approximately 2–4% of human
peripheral blood CD4+ T cells). However, CD25 by itself
has limitations as a marker for CD4+CD25high regulatory
T cells, as it is also up-regulated in activated effector T
cells. The recent discovery of low expression of CD127
(IL-7 receptor α) on CD4+CD25high regulatory T cells pro-
vides further delineation of this population [54-56]. How-
ever, some regulatory CD4+ T cells that are
Foxp3+CD127low express little-to-no CD25 [56].
Several other molecules associated with CD4+CD25high
regulatory T cells have been descsribed. In humans, these
cells constitutively express intracellular cytotoxic T-lym-
phocyte antigen 4 (CTLA-4) and glucocorticoid-induced
tumor-necrosis-factor-receptor-related protein (GITR).
Upon activation, they also express membrane-bound
TGF-β and HLA-DR [57]. Other surface markers report-
edly expressed on human CD4+CD25high regulatory T
cells include CD69, CD45RA/CD45RO, CD134 (OX40),
CD95, and programmed cell death-ligand 1 (PD-L1).
CD4+CD25high regulatory T cells also express chemokine
receptors to direct their migration to different tissues. Cur-
rent data suggest that signals from various chemokines
and integrin ligands determine which membrane chem-
okine receptors and integrins are expressed on
CD4+CD25high regulatory T cells. Similar to effector T
cells, CD62L (also known as L-selectin) and CCR7 are
important lymph node homing molecules for
CD4+CD25high regulatory T cells [58]. The majority of
CD4+CD25high regulatory T cells express CCR4 and CCR8
[59], but other chemokine receptors and integrin mole-
cules, such CD103, are also present. The expression level
of integrins dictates the direction of cell migration. For
example, CD4+CD25high CD103- regulatory T cells prefer-
entially migrate to lymph nodes, whereas CD4+CD25high
CD103+ regulatory T cells efficiently migrate into inflam-
matory sites [58]. Most human CD4+CD25high regulatory
T cells are believed to be in a late stage of differentiation.
This notion is supported by their expression of activation/
memory markers, as indicated above [60].
The absence of specific markers makes it difficult to isolate
pure populations of CD4+CD25high regulatory T cells, to
further characterize their phenotype. At least a small
number of non-regulatory activated effector T cells usually
contaminate isolated CD4+CD25high regulatory T cells,
due to the overlapping expression of CD25. Thus, strate-
gies to expand CD4+CD25high regulatory T cells for higher
yield and purity have been sought. Use of IL-2, a T cell
growth factor that induces proliferation of CD4+CD25high
regulatory T cells in vitro, was considered. However, IL-2
also favors the expansion of non-regulatory effector T
cells. Another candidate is the immunosuppressive drug
rapamycin (sirolimus), used for the prevention of organ
transplant rejection as well as resistant graft versus host
disease (GVHD) [61-63]. Human peripheral blood
CD4+CD25high regulatory T cells cultured in the presence
Surface markers associated with CD4+CD25high regulatory  T cells Figure 3
Surface markers associated with CD4+CD25high 
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of rapamycin survive and vigorously expand for at least 3
weeks, while effector T cells are inhibited from prolifera-
tion. This phenomenon is thought to result from differen-
tial intracellular signaling in CD4+CD25high regulatory T
cells compared to CD4+CD25- effector T cells in response
to rapamycin, which blocks progression from G1 into S
phase in activated effectors [64]. The rapamycin-expanded
CD4+CD25high regulatory T cells are suppressive and have
the same phenotype as freshly isolated blood
CD4+CD25high regulatory T cells. Thus, in vitro rapamycin
may allow the generation of highly efficient
CD4+CD25high regulatory T cells and better characteriza-
tion of their functions for potential clinical use [65,66].
CD4+CD25high regulatory T cell function
A key characteristic of CD4+CD25high regulatory T cells is
their in vitro anergy. In contrast to CD4+CD25- T cells,
which proliferate upon receiving T cell receptor (TCR)
stimulation, CD4+CD25high regulatory T cells are unre-
sponsive to this proliferative signal and do not produce
IL-2. However, CD4+CD25high regulatory T cells cultured
with anti-CD3 antibodies for TCR stimulation and exces-
sexogenous IL-2 overcome anergy and proliferate; block-
ing IL-2 inhibits this phenomemon [67]. The anergic state
of CD4+CD25high regulatory T cells can also be overcome
by anti-CD28 costimulation or interaction with mature
dendritic cells [68-70]. Interestingly, recent studies sug-
gest that CD4+CD25high regulatory T cells are not anergic
in vivo, but have a high turnover rate [71,72].
The second cardinal feature of CD4+CD25high regulatory T
cells is their ability to suppress immune responses
[72,73]. Suppression occurs when CD4+CD25high regula-
tory T cells are activated with antigens recognized by their
specific TCR, but can be maintained without further TCR
stimulation [74]. Thus, suppressive activity is antigen-
nonspecific. However, CD4+CD25high regulatory T cells
that share the same antigenic specificity with effector cells
are more suppressive. Similarly, allogeneic
CD4+CD25high  regulatory T cells are suppressive, but
autologous CD4+CD25high regulatory T cells are more
potent suppressors. Some studies suggest that
CD4+CD25high regulatory T cells inhibit proliferation of
effector CD4+CD25- T cells and CD8+ T cells by arresting
the proliferation of these cells at G1-S interphase of the
cell cycle [75]. Interestingly, the addition of exogenous IL-
2 does not overcome the suppression, suggesting unre-
sponsiveness at the level of the IL-2 receptor [72]
Contact-dependent suppression by CD4+CD25high regula-
tory T cells has been reported to occur via CTLA-4 signal-
ing: CTLA-4 blockade leads to diminished suppression of
effector T cell proliferation by CD4+CD25high regulatory T
cells [76,77]. Recent studies have suggested that multiple
CTLA-4 associated pathways could mediate suppression
by CD4+CD25high regulatory T cells. Preferential engage-
ment of CTLA-4, instead of CD28, with CD80/CD86 may
provide a negative proliferative signal [78]. Alternatively,
CTLA-4 on CD4+CD25high regulatory T cells may signal
dendritic cells to produce the immunosuppressive
cytokines, IL-10 and TGF-β [79]. In a novel mechanism,
suggested by results of Fallarino et al., CTLA-4 signals den-
dritic cells to produce high levels of the enzyme indoleam-
ine, which in turn breaks down tryptophan, an amino
acid important for T cell proliferation [80], and conse-
quentially inhibits the proliferation of effector T cells.
While the main targets of suppression by CD4+CD25high
regulatory T cells are innate and adaptive immune cells
[81], these regulatory T cells also participate in immune
responses against infectious agents [82], malignant cells
[83], and allogeneic organ and stem-cell grafts [84].
Although CD4+CD25high regulatory T cells regulate both
Th1 and Th2 immune responses, Th2 cells may partially
escape this suppressive activity via their ability to respond
to growth factors other than IL-2, such as IL-4, IL-7, and
IL-9 [85]. In contrast, the proliferation of Th1 cells is only
restored by the administration of IL-15 [85]. In mice, the
depletion of CD4+CD25high regulatory T cells prevents
antigen-induced Th2 differentiation by increasing the dif-
ferentiation of Th1 cells [86,87]. Under appropriate con-
ditions, CD4+CD25high  regulatory T cells are able to
confer suppressive capacity on CD4+CD25- T cells, con-
verting them to either Th3 or Tr1 cells [88,89].
CD4+CD25high regulatory T cells and autoimmunity
Several autoimmune disorders have been linked to physi-
cal and genetic alterations in thymus that disrupt the
development of nTreg. Thymectomized neonatal mice are
deficient in CD4+CD25high regulatory T cells and develop
multi-organ autoimmune disease, which can be overcome
by the adoptive transfer of CD25+ thymocytes from nor-
mal mice [90,91]. Children with thymic hypoplasia as a
result of the 22.q2 deletion syndrome display impaired
CD4+CD25high regulatory T cell generation and have an
increased risk of developing an autoimmune disorder
[92]. Mutations in Foxp3 result in the scurfy phenotype in
mice. Foxp3 mutant "scurfy" mice and Foxp3-null mice
lack CD4+CD25high regulatory T cells and die of a lym-
phoproliferative-wasting disease, likely due to uncon-
trolled expansion of effector T lymphocytes. Adoptive
transfer of CD4+CD25high regulatory T cells into neonatal
Foxp3-null or scurfy mice protects them temporarily from
disease [92,93].
Human patients with Foxp3 gene mutations develop IPEX
syndrome, a potentially fatal disorder, characterized by
immune dysregulation, polyendocrinopathy, and enter-
opathy (Table 1) [94-96]. IPEX CD4+CD25high regulatory
T cells are less suppressive, although their surface pheno-Pediatric Rheumatology 2008, 6:20 http://www.ped-rheum.com/content/6/1/20
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type and levels in peripheral blood remain normal [97].
Consequently, it is suggested that functional insufficiency
rather than defective differentiation of CD4+CD25high reg-
ulatory T cells may occur in these patients. Allogeneic
bone marrow transplantation in IPEX subjects is effective
in correcting Foxp3 associated dysfunctions [98], and clin-
ical recovery accompanies regeneration of functionally
competent CD4+CD25high regulatory T cells [99].
In addition to IPEX, many more common polygenic
autoimmune disorders, including multiple sclerosis, type
1 diabetes, are hypothesized to have abnormalities in
CD4+CD25high  regulatory T cell function [100-105].
Below, we consider this hypothesis and discuss findings
from studies of these cells in rheumatic diseases. Across
the spectrum of autoimmune diseases, it is not yet clear
whether changes in these cells are primary or secondary to
disease.
CD4+CD25high regulatory T cells in rheumatic diseases
In rheumatic diseases, most studies have focused on
CD4+CD25high regulatory T cells, while the roles of other
regulatory T cell types remain unclear (Table 2). Early
attempts to characterize CD4+CD25high regulatory T cells
were flawed due to use of high surface expression of CD25
as the single cell marker and the resulting inclusion of var-
iable numbers of activated T effector cells over the course
of disease. In addition, levels and/or activity of
CD4+CD25high regulatory T cells are influenced by differ-
ent immunosuppressive treatments. Therefore, future
studies that employ a better combination of markers (e.g.
CD4, CD25, and CD127) and consider medication status
and disease severity in the analysis will be important.
Nonetheless, current studies of CD4+CD25high regulatory
T cells in rheumatic diseases provide the scientific founda-
tion for further research.
Juvenile idiopathic arthritis (JIA)
Research on CD4+CD25high regulatory T cells in juvenile
idiopathic arthritis (JIA) has revealed distinct abnormali-
ties in function and distribution in various disease sub-
types. De Kleer et al. found reduced numbers of
circulating CD4+CD25high regulatory T cells in extended
oligoarticular JIA, compared to persistent oligoarticular
JIA [106]. The numbers of CD4+CD25high Foxp3+ regula-
tory T cells in the synovial fluid of inflamed joints were
comparable, but more CD4+CD25intermediate Foxp3+ regu-
latory T cells were present in persistent vs. extended oli-
goarticular JIA. Synovial fluid CD4+CD25high regulatory T
cells had more potent in vitro suppressive effects com-
pared to their peripheral blood counterparts, suggesting
possible functional enhancement of these cells in the
joints. In addition, CD4+CD25high regulatory T cells more
easily suppress peripheral blood CD4+CD25- T effector
cells than T effectors from synovial fluid, consistent with
in vitro findings on the effects of IL-1 and IL-6 on suscep-
tibility to suppression [107]. The authors conclude that
CD4+CD25high regulatory T cells cannot prevent disease
development, but synovial CD4+CD25high regulatory T
cells may contribute to reversal of ongoing inflammation
in persistent oligoarticular JIA [106,108].
In another study of synovial CD4+CD25high regulatory T
cells in persistent and extended oligoarticular JIA, Massa
et al. demonstrated that certain epitopes of human HSP
increase the frequency of CD4+CD25high regulatory T cells
and induce Foxp3 expression [109]. Reactivity of
CD4+CD25high regulatory T cells to these human HSP
epitopes appears to influence regulation of inflammation
in oligoarticular JIA [109].
In systemic JIA, circulating CD4+CD25high regulatory T
cell frequency was reported to be lower than healthy con-
trols [110]. Studies from our laboratory showed that cir-
culating CD4+CD25high  CD127lo/-  regulatory T cell
numbers are normal, but their in vitro suppressive func-
tion is lower than that of healthy controls (unpublished
data). This defect in CD4+CD25high  regulatory T cell-
mediated suppression does not appear to result from a
deficiency of CD45RA+ naïve cells, the more suppressive
subset of CD4+CD25high  CD127lo/-  regulatory T cells
Table 1: Characteristics of IPEX Syndrome #§.
Organ system Manifestations*
Endocrine Insulin dependent diabetes mellitus
Thyroid dysfunction
Parathyroid hormone resistance
Gastrointestinal Autoimmune enteropathy
Diarrhea
Villous atrophy, failure to thrive
Skin Eczema
Ichthyosiform dermatitis
Exfoliative dermatitis
Infectious disease Exaggerated response
to viral infections
Frequent infections
Immune dysregulation Increased IgE, intermittent eosinophilia
Skewing of T lymphocytes to Th2 phenotype
Hemolytic anemia
Immune thrombocytopenia
Coagulopathy
# Alternative names: XLAAD (X-linked autoimmunity allergic 
dysregulation syndrome); insulin dependent diabetes mellitus-
secretory diarrhea syndrome; XPID (Polyendocrinopathy, immune 
dysfunction, diarrhea, X-linked)
§ Treatment: immunosuppression (Cyclosporine A), allogeneic bone 
marrow transplantation
* Manifestations of the disease are highly variablePediatric Rheumatology 2008, 6:20 http://www.ped-rheum.com/content/6/1/20
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(unpublished data). In contrast, we find reduced levels of
circulating CD4+CD25high regulatory T cells in polyarticu-
lar JIA (unpublished data).
Ruprecht et al. [111] also investigated CD4+CD25high reg-
ulatory T cells in synovial fluid of patients with JIA. They
found that CD4+CD25high regulatory T cells expressing
surface CD27 exhibit a higher level of Foxp3 and have
stronger suppressive activity. They concluded that, used in
conjunction with CD25, CD27 is a useful marker to dis-
tinguish regulatory from effector T cells in inflamed tis-
sues. However, others have disputed the specificity of
CD27 as a CD4+CD25high regulatory T cell marker [112].
Another important issue is how various JIA treatments
affect CD4+CD25high regulatory T cell distribution and
function. It was reported that methotrexate and corticos-
teroids do not influence the frequency or activity of these
cells in JIA [106,110]. De Kleer et al. observed normaliza-
tion of levels of circulating CD4+CD25high regulatory T
cell after autologous stem cell transplantation (ASCT),
perhaps from the preferential homeostatic expansion of
CD4+CD25high regulatory T cells during the lymphopenic
phase of immune reconstitution. They postulated that
ASCT reprograms auto-reactive T cells and restores the
immune regulatory network of CD4+CD25high regulatory
T cells [110].
Rheumatoid arthritis (RA)
Reported data on frequency and activity of CD4+CD25high
regulatory T cells in rheumatoid arthritis (RA) are conflict-
ing. Liu et al. found the quantities and functional proper-
ties of CD4+CD25high  regulatory T cells in peripheral
blood of RA patients to be comparable to healthy control
Table 2: CD4+CD25high regulatory T cells in rheumatic diseases.
Disease Abnormalities associated with regulatory T cells Authors
JIA 1) ↓ numbers in extended oligoarticular JIA.
2) HSP epitopes induce ↑ numbers in synovial fluid.
3) ASCT induces restoration of normal numbers and immune 
tolerance.
4) Regulatory T cells from inflamed joints express CD27.
1) DeKleer et al., 2004 (106).
2) Massa et al., 2007 (109).
3) DeKleer et al., 2006 (110).
4) Ruprecht et al., 2005 (111).
RA 1) No change in numbers in peripheral blood, ↑ numbers in 
synovial fluid.
2) Anti-TNF-α treatment does not induce changes in numbers 
and function*.
3) Anti-TNF-α treatment induces ↑ in numbers and function *.
4) Synovial T cells are more resistant to suppression.
5) ↑ numbers of CCR5+ CXCR4+ regulatory T cells in 
synovial fluid.
6) Imbalance between IFN-γ producing cells and regulatory T 
cell numbers.
1) Cao et al., 2003 (108), Mottonen et al., 2005 (119).
2) Dombrecht et al., 2006 (115).
3) Ehrenstein et al., 2004 (117).
4) van Amelsfort et al., 2004 (116).
5) Jiao et al., 2007 (120).
6) Behrens et al., 2007 (121).
SLE 1) ↓ numbers during active disease*.
2) No change in numbers during clinical remission.
3) ↑ numbers*.
4) Treatment does not induce changes in numbers*.
5) Corticosteroid treatment induces ↑ numbers*.
6) IFN-α producing cells block suppressive function.
7) Positive correlation between numbers and disease severity*.
8) Inverse correlation between numbers and disease severity*.
9) Reversible functional defect in active disease.
1) Liu et al., 2004 (126); Mellor-Pita et al., 2006 (127).
2) Crispin et al., 2004 (128).
3) Azab et al., 2008 (129).
4) Cepika et al, 2007 (131)
5) Valencia et al., 2007 (132).
6) Yan et al., 2008 (134).
7) Mellor-Pita et al., 2006 (127).
8) Lin et al., 2007 (130).
9) Barath et al., 2007 (135).
Spondylo-arthropathy 1) No change in numbers and function. 1) Cao et al., 2003 (108).
Kawasaki disease 1) ↓ numbers in active disease; normalized numbers in 
defervescense.
1) Furuno et al., 2004 (138).
Sjogren's syndrome 1) ↑ numbers*.
2) ↓ numbers*.
1) Gottenberg et al., 2005 (136).
2) Li et al., 2007 (137).
Sarcoidosis 1) ↑ numbers; insufficient inhibition of TNF-α production.
2) ↓ regulatory T cell-associated genes in broncho-aveolar fluid 
T cells.
1) Miyara et al., 2003 (139).
2) Idali et al., 2008 (140).
* Conflicting results.Pediatric Rheumatology 2008, 6:20 http://www.ped-rheum.com/content/6/1/20
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subjects [113,114], while Cao et al. reported a decreased
frequency of CD4+CD25high regulatory T cells in periph-
eral blood of RA subjects [114]. Some studies found that
treatment with methotrexate, hydroxychloroquine, anti-
TNF-α, and systemic/intra-articular steroids does not
influence the abundance or suppressive function of
CD4+CD25high regulatory T cells [115-118], while others
reported increased levels and suppressive function with
TNF-α blockade [117,118].
Nevertheless, there is a consensus that synovial fluid in
inflamed joints is enriched in CD4+CD25high regulatory T
cells [113,114,119]. These synovial CD4+CD25high regu-
latory T cells express increased levels of inflammation-
related chemokine receptors, such as CCR4, CCR5, and
CXCR4 [120]. Like findings in JIA, evidence for the
increased resistance of RA synovial T effector cells to sup-
pression by CD4+CD25high regulatory T cells has been
reported [116]. Behrens et al. linked CD4+CD25high regu-
latory T cell dysfunction in RA to a disturbance in the
homeostatic relationship between CD4+CD25high regula-
tory T cells and Th1 cells in the synovium. CD4+CD25high
regulatory T cells from RA subjects are capable of sup-
pressing the production of IFN-γ by synovial membrane
Th1 lymphocytes [121]. However, the ratio of
CD4+CD25high regulatory T cells to IFN-γ producing cells
is lower in the synovial membrane than in synovial fluid
or blood. The authors suggest that the local imbalance
between Th1 and CD4+CD25high regulatory T cells may be
responsible for repeated rheumatic flares and could be a
target for future treatments [121].
Systemic lupus erythematosus (SLE)
Findings that central tolerance remains intact in murine
models of SLE suggest a critical breakdown of peripheral
tolerance in this disease [122-124]. Consistent with this
possibility, most studies in human SLE indicate that
CD4+CD25high regulatory T cell distribution is altered in
association with active disease. Numbers of circulating
CD4+CD25high regulatory T cells decrease in patients with
active SLE [125-127] while clinical remission is associated
with elevated or normal CD4+CD25high regulatory T cell
frequency [128-131]. A single study reported that disease
activity in SLE correlates positively with the numbers of
CD4+CD25high regulatory T cells [131].
In a study of CD4+CD25high regulatory T cell function,
Vallencia et al. claimed that a reversible defect occurs in
patients with SLE. CD4+CD25high regulatory T cells from
active but not inactive SLE patients were deficient in in
vitro suppressive activity and had decreased Foxp3 mRNA
and protein [132,133]. Opposite findings of increased
Foxp3 expression in active disease were reported in one
study of pediatric SLE [133]. Yan et al. found no difference
in Foxp3 expression in CD4+CD25high regulatory T cells of
SLE patients [134]. However, decreased suppressive func-
tion of CD4+CD25high regulatory T cells appeared to be a
consequence of inhibition by IFN-activated autologous
antigen presenting cells. These cells could also inhibit the
function of CD4+CD25high regulatory T cells from healthy
control subjects [135].
Other rheumatic diseases
The work on CD4+CD25high regulatory T cells in other
rheumatic diseases is limited to date. In primary Sjogren
syndrome, Gottenberg et al. reported an increase in circu-
lating CD4+CD25high regulatory T cells, and no change in
levels with methotrexate or corticosteroid treatment
[136]. However, a more recent report argues that the num-
bers of circulating CD4+CD25high regulatory T cells in
patients with Sjogren syndrome decrease [137].
In Kawasaki disease, Furuno et al. found that during the
active phase of the disease, the number of circulating
CD4+CD25high regulatory T cells is reduced compared to
patients with infectious causes of febrile illness, whose
CD4+CD25high regulatory T cell numbers are higher than
in healthy subjects. In defervesce phase of the disease, the
number of CD4+CD25high regulatory T cells in patients
with Kawasaki disease increases to/or above normal lev-
els, while CD4+CD25high regulatory T cells in patients
with infectious febrile disease decrease to normal levels
[138].
In spondyloarthropathy, a single study by Cao et al. found
normal levels of circulating CD4+CD25high regulatory T
cells, but a higher proportion of CD4+CD25high regulatory
T cells in synovial fluid of inflamed joints than in periph-
eral blood [114].
In sarcoidosis, Miyara et al. showed an increase in fre-
quency of CD4+CD25high regulatory T cells in sarcoid
granulomas, bronchoalveolar lavage fluid (BALF), and
peripheral blood of patients with active disease. The cells
reportedly exhibit powerful anti-proliferative activity, but
cannot completely inhibit TNF-α production. The authors
conclude that although sarcoidosis is associated with glo-
bal CD4+CD25high regulatory T cell amplification, the
cells are functionally insufficient to control local inflam-
mation [139]. In contrast, Idali et al. [140] found
decreased frequency of Foxp3+ cells among BALF and
blood CD4+ cells in sarcoidosis patients.
Mechanistic issues
Current data indicate that reduced numbers of circulating
CD4+CD25high regulatory T cells is not a general finding
in rheumatic diseases, while reduced function is more
commonly found. Several hypothetical defects in
CD4+CD25high regulatory T cell function that could lead
to autoimmunity have been proposed [141]. However,Pediatric Rheumatology 2008, 6:20 http://www.ped-rheum.com/content/6/1/20
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data pointing to a secondary effect on CD4+CD25high reg-
ulatory T cells in autoimmune disorders have also
emerged. The example of SLE is illustrative. Compromised
function could result from direct interaction between SLE-
associated auto-antigens and their cognate ligands on
CD4+CD25high  regulatory T cells [142]. Alternatively,
endogenous stimulants in SLE may activate antigen pre-
senting cells to produce alpha-interferon and related fac-
tors that inhibit CD4+CD25high regulatory T cell activity
[134]. Pro-inflammatory factors associated with autoim-
munity, such as IL-1, IL-6, and TNF-α, also can inhibit
CD4+CD25high regulatory T cell function [143-145]. The
resolution of this issue is central to a full understanding of
autoimmunity.
Increased suppressive potency of CD4+CD25high regula-
tory T cells at sites of inflammation has been reported in
several diseases. The relative importance of circulating ver-
sus tissue CD4+CD25high regulatory T cells requires more
study. One attractive possibility is that tissue
CD4+CD25high regulatory T cells may be more antigen-
specific, and consequentially more suppressive [106,116]
while circulating CD4+CD25high regulatory T cells may be
recruited to different tissues in response to inflammatory
conditions [146], and non-specifically augment suppres-
sion. The occasionally reported reduction in numbers of
CD4+CD25high regulatory T cells in the circulation may
result from their recruitment to sites of inflammation.
However, expansion of tissue localized and circulating
CD4+CD25high  regulatory T cells may occur during
autoimmune-associated inflammation [116]. Thus,
CD4+CD25high regulatory T cells may be actively recruited
or be generated de novo at sites of inflammation (or
both). It is anticipated that the development of new tech-
nologies that allow in vivo tracking of circulating
CD4+CD25high regulatory T cells will advance our current
understanding of migratory and suppressive potentials of
different subsets of CD4+CD25high  regulatory T cells.
Finally, the potent suppressive activity of CD4+CD25high
regulatory T cells at inflammatory sites is usually insuffi-
cient to control inflammation. One probable explanation
is that the presence of inflammatory cytokines at these
sites makes effector T cells more resistant to suppression.
In addition, the recently reported induction of highly
inflammatory Th17 cells from CD4+CD25high regulatory T
cells that are not terminally differentiated [147] suggests
that the latter may, under certain conditions, potentiate
rather than suppress inflammation.
CD4+CD25high regulatory T cells as a treatment in 
autoimmune and rheumatic diseases
There is a need to carefully control the size of the
CD4+CD25high  regulatory T cell population in vivo to
achieve a balance between the necessity to suppress auto-
reactivity and the ability to allow appropriate responses to
foreign and tumor antigens. Little is known of the mecha-
nisms of this control; however, the alterations in distribu-
tion and function of CD4+CD25high regulatory T cells in
autoimmune and rheumatic diseases suggest a role for the
therapeutic use of these cells. In mice with collage-
induced arthritis, depletion of CD4+CD25high regulatory T
cells causes rapid progression, and the transfer of isolated
and ex vivo-proliferated CD4+CD25high regulatory T cells
can reverse early joint damage [148]. Administration of
CD4+CD25high regulatory T cell also yields improvement
in murine models of colitis, autoimmune encephalomy-
elitis, diabetes, and allogeneic transplantion [149-152].
Human research has shown that some established thera-
pies may promote CD4+CD25high regulatory T cell devel-
opment and survival in vivo. For instance, monoclonal
antibody to CD20 (rituximab), which depletes B cells,
leads to a selective increase in CD4+CD25high regulatory T
cells [153]. Polyclonal antibody therapies, such as anti-
lymphocyte serum (ALS) and anti-thymocyte globulin
(ATG), have been shown to preferentially deplete T effec-
tor cells, and induce CD4+CD25high regulatory T cells
[154,155]. As described above, rapamycin preferentially
expands CD4+CD25high regulatory T cells. Therefore, a
major therapeutic effect of rapamycin may be the induc-
tion of tolerogenic CD4+CD25high regulatory T cells in
vivo.
Besides these established therapies, recent research has
focused on cytokine related therapies to modulate
CD4+CD25high regulatory T cell function. Among candi-
date cytokines are growth factors in the IL-2 family. These
cytokines signal via STAT5, the homeostatic pathway that
regulates CD4+CD25high regulatory T cell function. Sev-
eral studies have reported that these cytokines enhance
immune regulation by CD4+CD25high regulatory T cells.
For instance, IL-7 and IL-15 are involved in the preserva-
tion of optimal suppressive function by CD4+CD25high
regulatory T cells [156]. In addition, IL-15 administration
alone induces de novo generation of CD4+CD25high regu-
latory T cells [157]. The newly identified IL-35 has been
shown to trigger CD4+CD25high regulatory T cell expan-
sion and subsequent immune suppression [158]. How-
ever, the specificity of these cytokines for CD4+CD25high
regulatory T cells needs to be further examined to avoid
undesirable expansion of effector T cells.
In contrast to T cell growth factors, pro-inflammatory
cytokines have been shown to inhibit function of
CD4+CD25high regulatory T cells, possibly via promotion
of Th17 development [159]. Therefore, anti-TNF-α, anti-
IL1, anti-IL6, and anti-IL-21 therapies may affect inflam-
mation not only by direct inhibition of the pro-inflamma-
tory cytokines but also by reestablishment of immune
regulation by CD4+CD25high regulatory T cells. On thePediatric Rheumatology 2008, 6:20 http://www.ped-rheum.com/content/6/1/20
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other hand, short term treatment with high dose CTLA-4Ig
(abatacept), which has been shown to have anti-inflam-
matory properties in arthritis, leads to a precipitous loss of
CD4+CD25high regulatory T cells and, in some animal
models, exacerbation of autoimmunity [160].
Direct transfusion of CD4+CD25high regulatory T cell in
humans is starting to be explored as a therapy. We are
aware of two early trials in patients post stem cell trans-
plantation (SCT). In patients with allogeneic SCT, Matth-
ias Edinger and his team from the Department of
Hematology and Oncology at the University Hospital of
Regensburg, Germany are conducting a phase I clinical
trial (safety and feasibility) using CD4+CD25high regula-
tory T cells-enriched lymphocyte products (personal com-
munication). Patients with a high risk of relapse after
allogeneic SCT are preemptively treated with donor T cells
enriched with 50–60% of CD4+CD25high regulatory T
cells, in order to reduce GVHD. Eight patients have been
treated so far without complications. A trial using third
party cord blood CD4+CD25high  regulatory T cell in
patients with SCT has been recently initiated at the Uni-
versity of Minnesota (Dr. B. Balazar, personal communi-
cation). We are not aware of any established clinical trials
in autoimmune diseases, although CD4+CD25high regula-
tory T cell therapy will possibly be initiated in type 1 dia-
betes in the near future.
Despite encouraging data from animal models and early
human trials, a number of issues must be resolved for
optimal use of CD4+CD25high regulatory T cells as a ther-
apy [161,162]. Firstly, there are likely to be differences in
the specific role of CD4+CD25high regulatory T cells in par-
ticular diseases, and these must be elucidated. Secondly,
CD4+CD25high regulatory T cell-specific surface markers
remain elusive, which hampers the isolation of pure pop-
ulations of CD4+CD25high regulatory T cells. Third, the
use of autologous CD4+CD25high regulatory T cell clones
for particular auto-antigens would increase the effective-
ness and decrease potential side effects of "bystander"
suppression. This will require techniques for identifying
and expanding antigen specific clones of CD4+CD25high
regulatory T cells. Recent successes with CD4+CD25high
regulatory T cell expansion using rapamycin are promis-
ing in this regard [163,164]. Lastly, the fate of transfused
CD4+CD25high  regulatory T cells in vivo is not fully
known. In the unlikely event that CD4+CD25high regula-
tory T cells expand into tumor/effector cells or simply
become broadly immunosuppressive, there needs to be a
way to eliminate them from the body. Future therapies
may require the use of "designer" CD4+CD25high regula-
tory T cells that have been modified by gene transfer to
selectively express preferred proteins including antigen
specific TCR, homing receptors, cytokines, and "suicide"
genes [161,162]. Nevertheless, the manipulation of
CD4+CD25high  regulatory T cell function shows great
promise as a novel therapeutic option in autoimmune
and rheumatic diseases.
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